"The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.
No case of acute overdosage in humans has been described. The oral LD50 dose in rats was 1050 mg/kg and 437 mg/kg in mice.
HEXALEN® (altretamine) capsules is contraindicated in patients who have shown hypersensitivity to it. HEXALEN® (altretamine) capsules should not be employed in patients with preexisting severe bone marrow depression or severe neurologic toxicity. HEXALEN® (altretamine) capsules has been administered safely, however, to patients heavily pretreated with cisplatin and/or alkylating agents, including patients with preexisting cisplatin neuropathies. Careful monitoring of neurologic function in these patients is essential.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/9/2008
Additional Hexalen Information
Hexalen - User Reviews
Hexalen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.